{"DataElement":{"publicId":"2954716","version":"1","preferredName":"Plasma Cell Myeloma Chemosensitivity Type","preferredDefinition":"A description of the sensitivity of myeloma to chemotherapy.","longName":"2954714v1.0:4771392v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2954714","version":"1","preferredName":"Plasma Cell Myeloma Chemosensitivity","preferredDefinition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001)_Sensitivity of a malignancy to administration of chemotherapy, usually defined as the achievement of a partial response or better.","longName":"PCM_CHMOSTY","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2647790","version":"1","preferredName":"Myeloma","preferredDefinition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001) -- 2003","longName":"C3242","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Multiple Myeloma","conceptCode":"C3242","definition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"32446690-9562-2995-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-06","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-06-06","modifiedBy":"ONEDATA","dateModified":"2007-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2954712","version":"1","preferredName":"Chemosensitivity","preferredDefinition":"Sensitivity of a malignancy to administration of chemotherapy, usually defined as the achievement of a partial response or better.","longName":"C71488","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chemosensitivity","conceptCode":"C71488","definition":"Sensitivity of a malignancy to administration of chemotherapy, usually defined as the achievement of a partial response or better.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"765EB49C-413A-F476-E040-BB89AD43561B","latestVersionIndicator":"Yes","beginDate":"2009-10-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2009-10-20","modifiedBy":"ONEDATA","dateModified":"2009-10-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2842596","version":"1","preferredName":"Outcome of Therapy","preferredDefinition":"The result of therapy for a given disease or condition in a patient or group of patients.","longName":"C18919 ","context":"NCIP","contextVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"63D982FA-DFBF-58C7-E040-BB89AD433E84","latestVersionIndicator":"Yes","beginDate":"2009-02-26","endDate":null,"createdBy":"CURTIST","dateCreated":"2009-02-26","modifiedBy":"CURTIST","dateModified":"2009-02-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"765EB49C-414B-F476-E040-BB89AD43561B","latestVersionIndicator":"Yes","beginDate":"2009-10-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2009-10-20","modifiedBy":"KUMMEROA","dateModified":"2021-06-24","changeDescription":". 2021-6-24 ak Released per Janet review.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"4771392","version":"1","preferredName":"Plasma Cell Myeloma Chemosensitivity Type","preferredDefinition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001)_Sensitivity of a malignancy to administration of chemotherapy, usually defined as the achievement of a partial response or better._Something distinguishable as an identifiable class based on common qualities.","longName":"4771392v1.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Unknown","valueDescription":"Unknown","ValueMeaning":{"publicId":"2565695","version":"1","preferredName":"Unknown","longName":"2565695","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-CDAC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-02-26","endDate":null,"createdBy":"MEDVEDOH","dateCreated":"2003-02-26","modifiedBy":"MMADDINENI","dateModified":"2024-02-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"12D52D96-6FE6-3C2B-E050-BB89AD4344D3","beginDate":"2015-04-03","endDate":null,"createdBy":"NYCHM","dateCreated":"2015-04-03","modifiedBy":"ONEDATA","dateModified":"2015-04-03","deletedIndicator":"No"},{"value":"Not applicable","valueDescription":"Not applicable","ValueMeaning":{"publicId":"4771393","version":"1","preferredName":"Not applicable","longName":"4771393","preferredDefinition":"no chemotherapy, or chemotherapy ended more than 6 months prior to the preparative regimen.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"12D52D96-6FF0-3C2B-E050-BB89AD4344D3","latestVersionIndicator":"Yes","beginDate":"2015-04-03","endDate":null,"createdBy":"NYCHM","dateCreated":"2015-04-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"12D52D96-7009-3C2B-E050-BB89AD4344D3","beginDate":"2015-04-03","endDate":null,"createdBy":"NYCHM","dateCreated":"2015-04-03","modifiedBy":"ONEDATA","dateModified":"2015-04-03","deletedIndicator":"No"},{"value":"Resistant","valueDescription":"Resistant","ValueMeaning":{"publicId":"4771394","version":"1","preferredName":"Resistant","longName":"4771394","preferredDefinition":"less than 50 percent reduction of Ig level, or less than 90 percent reduction in urinary light chains in light chain only disease, or less than 50 percent reduction of plasma cells in bone marrow for nonsecretory myeloma (includes disease status of SD and PD).","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"12D52D96-7013-3C2B-E050-BB89AD4344D3","latestVersionIndicator":"Yes","beginDate":"2015-04-03","endDate":null,"createdBy":"NYCHM","dateCreated":"2015-04-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"12D52D96-702C-3C2B-E050-BB89AD4344D3","beginDate":"2015-04-03","endDate":null,"createdBy":"NYCHM","dateCreated":"2015-04-03","modifiedBy":"ONEDATA","dateModified":"2015-04-03","deletedIndicator":"No"},{"value":"Sensitive","valueDescription":"Sensitive","ValueMeaning":{"publicId":"4771395","version":"1","preferredName":"Sensitive","longName":"4771395","preferredDefinition":"greater than or equal to 50 percent reduction in Ig level, or greater than or equal to 90 percent reduction in urinary light chains in light chain only disease, or greater than or equal to 50 percent reduction of plasma cells in bone marrow for nonsecretory myeloma (includes disease status of sCR, CR, VGPR and PR).","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"12D52D96-7036-3C2B-E050-BB89AD4344D3","latestVersionIndicator":"Yes","beginDate":"2015-04-03","endDate":null,"createdBy":"NYCHM","dateCreated":"2015-04-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"12D52D96-704F-3C2B-E050-BB89AD4344D3","beginDate":"2015-04-03","endDate":null,"createdBy":"NYCHM","dateCreated":"2015-04-03","modifiedBy":"ONEDATA","dateModified":"2015-04-03","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"4771391","version":"1","preferredName":"Plasma Cell Myeloma Chemosensitivity Type","preferredDefinition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001):Sensitivity of a malignancy to administration of chemotherapy, usually defined as the achievement of a partial response or better.:Something distinguishable as an identifiable class based on common qualities.","longName":"C3242:C71488:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Multiple Myeloma","conceptCode":"C3242","definition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Chemosensitivity","conceptCode":"C71488","definition":"Sensitivity of a malignancy to administration of chemotherapy, usually defined as the achievement of a partial response or better.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"12D52D96-6FBF-3C2B-E050-BB89AD4344D3","latestVersionIndicator":"Yes","beginDate":"2015-04-03","endDate":null,"createdBy":"NYCHM","dateCreated":"2015-04-03","modifiedBy":"ONEDATA","dateModified":"2015-04-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"12D52D96-6FD0-3C2B-E050-BB89AD4344D3","latestVersionIndicator":"Yes","beginDate":"2015-04-03","endDate":null,"createdBy":"NYCHM","dateCreated":"2015-04-03","modifiedBy":"KUMMEROA","dateModified":"2021-06-24","changeDescription":". 2021-6-24 ak Released per Janet review.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2695319","version":"1","longName":"NMDP: CDEs to review","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"2964888","version":"1","longName":"2016r1: Myeloma Pre-HSCT Data","context":"NHLBI"}]}],"AlternateNames":[{"name":"mye_base_chem_sen_prep_kn","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"Specify the sensitivity of my","type":"Preferred Question Text","description":"Specify the sensitivity of myeloma to chemotherapy:","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"765EB49C-4179-F476-E040-BB89AD43561B","latestVersionIndicator":"Yes","beginDate":"2009-10-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2009-10-20","modifiedBy":"KUMMEROA","dateModified":"2021-06-24","changeDescription":". 2021-6-24 ak Released per Janet review. System generated def displayed as alt def. AK 4/6/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}